This study will look at how well a one time dose of Natalizumab will help with improving the recovery of a stroke. The participation in this study will last approximately 90 days.
The ARAMIS registry is designed to provide important and timely insight into the management of acute stroke patients who are on NOA in community practice. The primary goal is to address several key treatment and management issues surrounding patients with either AIS or ICH on anticoagulant therapy. In particular, attention will be focused on coagulation tests, utilization of thrombolytic therapy
for AIS, treatment patterns and clinical outcomes for AIS and ICH patients on anticoagulant therapy. The acquisition of such findings will be of critical importance to help fill in gaps on guideline recommendations and provide insights into the management of AIS and ICH patients on treatment with
new anticoagulants. This will allow physicians to feel more confident in anticoagulation therapy while improving the care and outcomes of patients on these agents who have stroke complications.
CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials. One trial will assess treatment differences between intensive medical management alone compared to carotid endarterectomy procedure plus intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to carotid artery stenting plus intensive medical management. Intensive medical management will involve control of blood pressure, LDL cholesterol, cigarette smoking, and other vascular risk factors.
The NAVIGATE ESUS trial involves the secondary prevention of stroke and prevention of systemic embolism in patients with a recent stroke of undetermined source. The study will compare rivaroxaban (anticoagulant) to the current standard of care, aspirin.
The purpose of this study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a TIA or minor ischemic stroke.